<DOC>
	<DOCNO>NCT01478633</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety galantamine patient fail benefit donepezil ( patient switch donepezil ) . In clinical practice , expect galantamine use patient switch donepezil due insufficient efficacy donepezil .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Galantamine Patients With Dementia Alzheimer 's Type Who Failed Benefit From Donepezil</brief_title>
	<detailed_description>This nonrandomized ( study drug intentionally assign ) , open-label ( people involve know identity intervention ) , single-arm ( one group patient receive treatment ) , multi-centered study galantamine patient Alzheimer 's disease ( AD ) . Galantamine approve treatment mild moderate dementia AD . Galantamine available film-coated tablet 68 country include United States Europe , also available oral syrup extended-release capsule 65 county . In Japan , galantamine approve January 2011 available three dosage form film-coated tablet , oral disintegrant tablet , oral syrup . The target population patient mild moderate dementia Alzheimer 's type ( ie , Mini-Mental State Examination [ MMSE ] range 10 22 ) fail benefit donepezil . Patients must diagnosis probable AD accord diagnostic criterion National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS-ADRDA ) study group . To ensure least 100 subject complete study , 125 subject enrol . The treatment group receive flexible dose 16 mg/day 24 mg/day . Patients receive study treatment 24 week accordance dose regimen specify protocol .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Have diagnosis probable Alzheimer 's disease ( AD ) accordance diagnostic criterion NINCDSADRDA study group Have MMSE score 10 22 inclusive screening Have take donepezil stably 5 mg/day 6 month screen Have progression ( worsen ) impair cognitive function 6 month longer screen Be consider medically stable investigator basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen Be medically stable basis clinical laboratory test perform screening Has concurrent neurodegenerative disease manifest dementia Dementia Alzheimer 's type Has suspect impaired cognitive function due variety cause Has significant health disorder diseases accord investigator ' detail criterion Has major surgery within 52 week screen , fully recover surgery , plan surgery time subject expect participate study Is woman pregnant , breastfeeding , plan become pregnant man plan father child enrol study Has history severe drug allergy severe drug hypersensitivity Has history drug alcohol abuse Used another investigational drug within 90 day screen Used antidementia drug market developed donepezil medication contain active ingredient within 6 month screen Is consider ineligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Donepezil</keyword>
</DOC>